Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $511,400.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $102.28, for a total transaction of $511,400.00. Following the transaction, the director now owns 157,557 shares of the company’s stock, valued at $16,114,929.96. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Blueprint Medicines Stock Up 2.3 %

Shares of NASDAQ BPMC opened at $104.89 on Thursday. The stock has a 50 day moving average price of $93.75 and a 200 day moving average price of $95.29. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of -49.71 and a beta of 0.61. Blueprint Medicines Co. has a 52-week low of $72.24 and a 52-week high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business’s revenue was up 126.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.20) EPS. Sell-side analysts expect that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BPMC. Stephens restated an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Wedbush reissued an “outperform” rating and set a $124.00 target price (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday. HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th. Finally, Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $122.72.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC bought a new position in shares of Blueprint Medicines during the second quarter valued at approximately $1,060,000. Federated Hermes Inc. lifted its holdings in Blueprint Medicines by 27.8% during the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after buying an additional 13,579 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Blueprint Medicines by 48.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after acquiring an additional 82,693 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter valued at $999,000. Finally, Fred Alger Management LLC raised its position in shares of Blueprint Medicines by 187.3% in the 2nd quarter. Fred Alger Management LLC now owns 48,588 shares of the biotechnology company’s stock worth $5,237,000 after acquiring an additional 31,675 shares in the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.